S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

NYSE:BHC - Bausch Health Companies Stock Price, Forecast & News

$26.46
-1.59 (-5.67 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
$25.16
Now: $26.46
$26.54
50-Day Range
$26.46
MA: $28.60
$30.25
52-Week Range
$18.72
Now: $26.46
$31.97
Volume13.54 million shs
Average Volume3.41 million shs
Market Capitalization$9.33 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone514-744-6792

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.38 billion
Cash Flow$11.76 per share
Book Value$8.05 per share

Profitability

Net Income$-4,148,000,000.00

Miscellaneous

Employees21,100
Market Cap$9.33 billion
Next Earnings Date2/19/2020 (Confirmed)
OptionableOptionable

Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.


Bausch Health Companies (NYSE:BHC) Frequently Asked Questions

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc (NYSE:BHC) announced its quarterly earnings results on Tuesday, August, 7th. The company reported $0.93 EPS for the quarter, beating the Zacks' consensus estimate of $0.81 by $0.12. The company had revenue of $2.13 billion for the quarter, compared to analysts' expectations of $2.05 billion. Bausch Health Companies had a negative net margin of 7.25% and a positive return on equity of 56.19%. View Bausch Health Companies' Earnings History.

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Bausch Health Companies.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies updated its FY 2020 Pre-Market earnings guidance on Wednesday, February, 19th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $8.65-8.85 billion, compared to the consensus revenue estimate of $8.78 billion.

What price target have analysts set for BHC?

15 equities research analysts have issued 12 month target prices for Bausch Health Companies' stock. Their forecasts range from $18.00 to $60.00. On average, they expect Bausch Health Companies' stock price to reach $34.13 in the next twelve months. This suggests a possible upside of 29.0% from the stock's current price. View Analyst Price Targets for Bausch Health Companies.

What is the consensus analysts' recommendation for Bausch Health Companies?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 1 sell rating, 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bausch Health Companies.

What are Wall Street analysts saying about Bausch Health Companies stock?

Here are some recent quotes from research analysts about Bausch Health Companies stock:
  • 1. According to Zacks Investment Research, "Bausch’s Bausch + Lomb/International and Salix segments maintain momentum on the back of several established brands, such as Xifaxan, BioTrue ONEday and Bausch + Lomb ULTRA. Newer products, such as Lumify and Thermage FLX, continue to perform well too. The initial uptake of psoriasis lotion, Duobrii, has been encouraging as well. After a tumultuous period, the company started a rebuilding process. Bausch has narrowed its focus on seven products — Vyzulta, Siliq, Bryhali, Lumify, Duobrii, Relistor and SiHy Daily. These have now been launched and hence the company’s performance is expected to be strong. However, the dermatology market continues to be challenging. Shares have outperformed the industry in the year so far." (12/16/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We employ a cash EPS multiple-based approach. The cash EPS number is derived from our adjusted 12-month income, which employs a total 12-month adjusted (non-GAAP) income projection of roughly $1.6B, which we divide by approximately 357M shares outstanding to derive our 12-month cash EPS of $4.46 per share." (8/7/2019)
  • 3. Cantor Fitzgerald analysts commented, "We rate BHC as 12-month price target of $32. A greater appreciation for BHC’s solid execution and future growth prospects under the new management team should drive upwards earnings revisions in 2019+, multiple expansion, and BHC shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $32." (4/25/2019)

Has Bausch Health Companies been receiving favorable news coverage?

News stories about BHC stock have trended neutral this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bausch Health Companies earned a news impact score of 0.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Bausch Health Companies.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 18,100,000 shares, an increase of 20.5% from the December 31st total of 15,020,000 shares. Based on an average daily trading volume, of 3,860,000 shares, the days-to-cover ratio is presently 4.7 days. Approximately 5.2% of the company's stock are short sold. View Bausch Health Companies' Current Options Chain.

Who are some of Bausch Health Companies' key competitors?

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Constellation Software (CSU), Gilead Sciences (GILD), Intact Financial (IFC), Micron Technology (MU), Netflix (NFLX), Alibaba Group (BABA), Bank of America (BAC), Twitter (TWTR), NVIDIA (NVDA) and Tesla (TSLA).

Who are Bausch Health Companies' key executives?

Bausch Health Companies' management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 64)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 63)
  • Mr. Thomas J. Appio, Pres & Co-Head Bausch + Lomb/International (Age 57)
  • Mr. William D. Humphries, Pres of Ortho-Dermatologics (Age 53)
  • Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 47)

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FIL Ltd (7.65%), Renaissance Technologies LLC (3.54%), Connor Clark & Lunn Investment Management Ltd. (1.32%), Thrivent Financial for Lutherans (0.68%), FMR LLC (0.54%) and CIBC World Markets Inc. (0.54%). Company insiders that own Bausch Health Companies stock include Christina Ackermann, John Paulson, Joseph C Papa, Mark C Mckenna, Paul Herendeen, Schutter Richard U De, Thomas Appio and William D Humphries. View Institutional Ownership Trends for Bausch Health Companies.

Which major investors are selling Bausch Health Companies stock?

BHC stock was sold by a variety of institutional investors in the last quarter, including Connor Clark & Lunn Investment Management Ltd., Cannell Peter B & Co. Inc., Commerzbank Aktiengesellschaft FI, FIL Ltd, Man Group plc, Russell Investments Group Ltd., M.D. Sass Investors Services Inc. and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Bausch Health Companies company stock in the last year include Christina Ackermann and Mark C Mckenna. View Insider Buying and Selling for Bausch Health Companies.

Which major investors are buying Bausch Health Companies stock?

BHC stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Fiera Capital Corp, Capital World Investors, MUFG Securities EMEA plc, Lakewood Capital Management LP, Redwood Capital Management LLC and Cubist Systematic Strategies LLC. Company insiders that have bought Bausch Health Companies stock in the last two years include John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De, Thomas Appio and William D Humphries. View Insider Buying and Selling for Bausch Health Companies.

How do I buy shares of Bausch Health Companies?

Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $26.46.

How big of a company is Bausch Health Companies?

Bausch Health Companies has a market capitalization of $9.33 billion and generates $8.38 billion in revenue each year. The company earns $-4,148,000,000.00 in net income (profit) each year or $4.02 on an earnings per share basis. Bausch Health Companies employs 21,100 workers across the globe.View Additional Information About Bausch Health Companies.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is http://www.bauschhealth.com/.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at 514-744-6792 or via email at [email protected]


MarketBeat Community Rating for Bausch Health Companies (NYSE BHC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  291 (Thanks for Voting!)
Underperform Votes:  319 (Thanks for Voting!)
Total Votes:  610
MarketBeat's community ratings are surveys of what our community members think about Bausch Health Companies and other stocks. Vote "Outperform" if you believe BHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel